title: Anterior ischemic optic neuropathy following intravitreal bevacizumab.
authors.forename: Jane Y
authors.initials: JY
authors.lastname: Huang
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ozaki
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Hayashi
authors.forename: Eiichi
authors.initials: E
authors.lastname: Uchio
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D003930:Diabetic Retinopathy / Q000188:drug therapy; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced* / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab